40 Participants Needed

Atezolizumab After Adoptive Cell Transfer for Cancer

Recruiting at 8 trial locations
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Breakthrough TherapyThis drug has been fast-tracked for approval by the FDA given its high promise
Approved in 2 JurisdictionsThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

This pilot phase I trial studies the side effects of atezolizumab in treating patients with cancer following adoptive cell transfer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Will I have to stop taking my current medications?

The trial requires that you stop any anti-cancer therapy, including adoptive cell transfer, for 28 days before starting atezolizumab. Additionally, you must not take systemic immunosuppressive medications within 2 weeks before starting the trial. Other medications, like hormone-replacement therapy or oral contraceptives, are allowed.

What data supports the effectiveness of the drug Atezolizumab (Tecentriq) for cancer treatment?

Atezolizumab has shown promising results in treating various cancers, including bladder cancer, where it improved response rates and survival compared to other treatments. It has also been effective in non-small cell lung cancer and triple-negative breast cancer, leading to its approval for these conditions.12345

Is atezolizumab generally safe for humans?

Atezolizumab, also known as Tecentriq, has been approved for use in several cancers and is generally considered to have an acceptable safety profile. Common side effects include fatigue, decreased appetite, and nausea, while more serious but less common effects can include lung inflammation, liver inflammation, and thyroid issues.46789

How is the drug atezolizumab unique in cancer treatment?

Atezolizumab is unique because it is a monoclonal antibody that targets PD-L1, a protein that helps cancer cells evade the immune system. By blocking this protein, atezolizumab enhances the body's immune response against tumors, making it different from traditional chemotherapy that directly targets cancer cells.124510

Research Team

Marcus Butler | Immunology

Marcus Butler

Principal Investigator

University Health Network Princess Margaret Cancer Center LAO

Eligibility Criteria

Adults with advanced cancers not responding to standard treatments, who've had adoptive cell transfer (ACT), can join. They need a life expectancy over 3 months, certain blood and organ function levels, no recent cancer therapies except ACT, and measurable disease. Pregnant women or those with severe allergies to antibodies, active infections, or autoimmune diseases that could worsen are excluded.

Inclusion Criteria

My leukemia or lymphoma can be measured for treatment response.
My side effects from previous cancer treatments are mild, except for possible hair loss, skin changes, or hormone issues.
I agree to use birth control during and 5 months after the study due to risks to a fetus.
See 19 more

Exclusion Criteria

I haven't had chemotherapy or radiotherapy in the last 4 weeks and have recovered from any side effects.
I haven't taken any immune-weakening medications in the last 2 weeks.
I do not have any serious illnesses or social situations that would stop me from following the study's requirements.
See 20 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive atezolizumab intravenously over 30-60 minutes on day 1, with cycles repeating every 21 days for a total of 17 doses over up to 12 months

12 months
17 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment completion, with follow-up at 4 weeks, 8 weeks, and then every 3 months

Up to 1 year
Multiple visits (in-person)

Treatment Details

Interventions

  • Atezolizumab
Trial OverviewThe trial is testing Atezolizumab's safety in patients after ACT therapy. It involves imaging tests like MRI and CT scans before and after treatment to see how the cancer responds. The study also includes biopsies and lab analyses to understand the drug's effects on tumors.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Treatment (atezolizumab)Experimental Treatment6 Interventions
Patients receive atezolizumab IV over 30- 60 minutes on day 1. Cycles repeat every 21 days for a total of 17 doses over up to 12 months in the absence of disease progression or unacceptable toxicity. Patients undergo CT, MRI, and biopsy on study. Patients also undergo blood sample collection on study.

Atezolizumab is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as Tecentriq for:
  • Melanoma
  • Hepatocellular carcinoma
  • Small cell lung cancer
  • Non-small cell lung cancer
  • Urothelial carcinoma
🇪🇺
Approved in European Union as Tecentriq for:
  • Melanoma
  • Hepatocellular carcinoma
  • Small cell lung cancer
  • Non-small cell lung cancer
  • Urothelial carcinoma

Find a Clinic Near You

Who Is Running the Clinical Trial?

National Cancer Institute (NCI)

Lead Sponsor

Trials
14,080
Recruited
41,180,000+

Findings from Research

Atezolizumab, the first anti-PD-L1 monoclonal antibody approved by the FDA, has shown promising efficacy in treating metastatic triple-negative breast cancer, supported by data from the Phase III IMpassion130 trial.
The review highlights the pharmacodynamic and pharmacokinetic properties of atezolizumab, emphasizing its safety and effectiveness in various cancers, including small-cell lung cancer and renal cell cancer.
Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer.Mavratzas, A., Seitz, J., Smetanay, K., et al.[2020]
Atezolizumab is an FDA-approved treatment for advanced bladder cancer that works by blocking the PD-L1/PD-1 immune checkpoint, enhancing T-cell immunity against tumors.
In clinical trials, atezolizumab showed a 15% objective response rate in patients whose cancer progressed after chemotherapy, and a 24% response rate in chemotherapy-naïve patients, with a favorable safety profile compared to other second-line treatments.
Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer.Inman, BA., Longo, TA., Ramalingam, S., et al.[2022]
Atezolizumab is a monoclonal antibody that targets PD-L1, which is being developed for treating various blood cancers and solid tumors, showing promise in cancer immunotherapy.
It has already been approved in the US as a second-line treatment for urothelial carcinoma and is pending approval for non-small cell lung cancer, highlighting its potential efficacy in these conditions.
Atezolizumab: First Global Approval.Markham, A.[2019]

References

Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer. [2020]
Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer. [2022]
Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. [2019]
Atezolizumab: First Global Approval. [2019]
FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC. [2020]
Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study. [2020]
Possible atezolizumab-associated acute kidney injury and immune thrombocytopenia. [2022]
Atezolizumab as the First Systemic Therapy Approved for Alveolar Soft Part Sarcoma. [2023]
U.S. Food and Drug Administration Approval Summary: Atezolizumab for Metastatic Non-Small Cell Lung Cancer. [2022]
[Atezolizumab (Tecentriq®): Activity, indication and modality of use in advanced or metastatic urinary bladder carcinoma]. [2019]